# A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

> **NCT03847649** · PHASE2 · RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 60 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Prednisone
- **DRUG:** Prednisone
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03847649
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-09
- **Primary completion:** 2030-04-30
- **Final completion:** 2031-04-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03847649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03847649, "A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03847649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*